GLPGF (Lakefront Biotherapeutics NV) Cyclically Adjusted Book per Share: $50.49 (As of Mar. 2026)


GLPGF Lakefront Biotherapeutics NV GLPGF
62 GF Score
Price $28.08
GF Value $136.98
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Cyclically Adjusted Book per Share?

Lakefront Biotherapeutics NV GLPGF 62 Cyclically Adjusted Book per Share is $50.49 as of Mar. 2026. GuruFocus rates GLPGF with a GF Score™ of 62/100 and a GF Value™ of $136.98 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lakefront Biotherapeutics NV's adjusted book value per share for the three months ended in Mar. 2026 was $57.076. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $50.49 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lakefront Biotherapeutics NV's average Cyclically Adjusted Book Growth Rate was 8.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 18.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lakefront Biotherapeutics NV was 23.50% per year. The lowest was 12.00% per year. And the median was 18.20% per year.

As of today (2026-06-25), Lakefront Biotherapeutics NV's current stock price is $28.08. Lakefront Biotherapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $50.49. Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio of today is 0.56.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lakefront Biotherapeutics NV was 11.89. The lowest was 0.58. And the median was 1.23.


Lakefront Biotherapeutics NV  (OTCPK:GLPGF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=28.08/50.49
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lakefront Biotherapeutics NV was 11.89. The lowest was 0.58. And the median was 1.23.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lakefront Biotherapeutics NV Cyclically Adjusted Book per Share Related Terms


Lakefront Biotherapeutics NV Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Cyclically Adjusted Book per Share Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.37 29.08 29.13 36.49 43.59

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.25 42.87 43.25 43.59 50.49

GLPGF vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Cyclically Adjusted PB Ratio falls into.


GLPGF
62GF Score
Lakefront Biotherapeutics NV GLPGF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lakefront Biotherapeutics NV's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=57.076/135.0710*135.0710
=57.076

Current CPI (Mar. 2026) = 135.0710.

Lakefront Biotherapeutics NV Quarterly Data

Book Value per Share CPI Adj_Book
201606 17.784 102.267 23.489
201609 17.199 102.118 22.749
201612 17.302 102.614 22.775
201703 17.299 103.972 22.473
201706 23.613 103.902 30.696
201709 0.000 104.170 0.000
201712 23.512 104.804 30.302
201803 21.644 105.419 27.732
201806 20.154 106.063 25.666
201809 25.534 106.618 32.348
201812 25.363 107.252 31.942
201903 24.325 107.876 30.457
201906 23.566 107.896 29.501
201909 45.068 107.470 56.643
201912 49.410 108.065 61.758
202003 48.414 108.550 60.242
202006 47.859 108.540 59.557
202009 48.889 108.441 60.895
202012 49.664 108.511 61.820
202103 49.091 109.522 60.543
202106 48.975 110.305 59.971
202109 46.990 111.543 56.902
202112 45.564 114.705 53.654
202203 44.400 118.620 50.558
202206 42.569 120.948 47.540
202209 40.460 124.120 44.030
202212 40.645 126.578 43.372
202303 41.668 126.528 44.481
202306 42.483 125.973 45.551
202309 42.458 127.083 45.127
202312 46.263 128.292 48.707
202403 47.753 130.552 49.406
202406 47.540 130.691 49.133
202409 48.213 130.968 49.723
202412 46.033 132.346 46.981
202503 45.081 134.348 45.324
202506 46.275 133.495 46.821
202509 43.584 133.743 44.017
202512 57.500 135.071 57.500
202603 57.076 135.071 57.076

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $50.49 mean?
Lakefront Biotherapeutics NV (GLPGF) has a Cyclically Adjusted Book per Share of $50.49 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Cyclically Adjusted Book per Share too high?
Lakefront Biotherapeutics NV's current Cyclically Adjusted Book per Share is $50.49. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Cyclically Adjusted Book per Share of $50.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Cyclically Adjusted Book per Share is $50.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (GLPGF) is currently considered Possible Value Trap. The stock's GF Value™ is $136.98, compared to a current price of $28.08 — trading 79.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is $50.49. Lakefront Biotherapeutics NV's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current Cyclically Adjusted Book per Share is $50.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of $28.08 is trading 79.5% below its estimated GF Value™ of $136.98. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for GLPGF:

  • Cyclically Adjusted Book per Share: $50.49
  • GF Value™: $136.98 vs. price of $28.08 (79.5% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
62GF Score

Get the complete analysis for GLPGF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.08
Price
$136.98
GF Value